Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Masking Description: Outcome assessors and data analysists will be blindedPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 79 years
- Gender
- Both males and females
Description
Compare 3-year overall survival between concurrent chemoradiotherapy and esophagectomy among patients who require additional treatment for esophageal squamous cell carcinoma endoscopically resected but found to have pT1b (submucosal invasion) or lymphovascular invasion Compare disease-free survival ...
Compare 3-year overall survival between concurrent chemoradiotherapy and esophagectomy among patients who require additional treatment for esophageal squamous cell carcinoma endoscopically resected but found to have pT1b (submucosal invasion) or lymphovascular invasion Compare disease-free survival between concurrent chemoradiotherapy and esophagectomy in the same study population Compare quality of life between concurrent chemoradiotherapy and esophagectomy in the same study population Compare treatment-related adverse event between concurrent chemoradiotherapy and esophagectomy in the same study population
Tracking Information
- NCT #
- NCT03306901
- Collaborators
- Ministry of Health & Welfare, Korea
- Investigators
- Principal Investigator: Jae Ill Zo, MD, PhD Samsung Medical Center
Get Well Soon